The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target (Q38235454)

31 August 2017

The role of fibroblast growth factor 21 in the pathogenesis of liver disease: a novel predictor and therapeutic target (English)

1 reference

31 August 2017

0 references

1 reference

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Wen-Yue Liu

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Keqing Shi

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

author name string

Sha Huang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Chen-Chen Zhao

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Li-Li Chen

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Martin Braddock

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Yong-Ping Chen

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

Wen-Ke Feng

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

language of work or name

English

0 references

publication date

31 July 2014

1 reference

Expert Opinion on Therapeutic Targets

31 August 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

volume

18

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

31 May 2020

page(s)

1305-1313

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:25077735%20AND%20SRC:MED&resulttype=core&format=json

Adipose fibroblast growth factor 21 is up-regulated by peroxisome proliferator-activated receptor gamma and altered metabolic states.

31 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Fibroblast growth factor 21: a promising therapeutic target in obesity-related diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Identification of a novel FGF, FGF-21, preferentially expressed in the liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Thermogenic activation induces FGF21 expression and release in brown adipose tissue.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Time-imposed daily restricted feeding induces rhythmic expression of Fgf21 in white adipose tissue of mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

The FGF family: biology, pathophysiology and therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

βKlotho is required for fibroblast growth factor 21 effects on growth and metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Treating diabetes and obesity with an FGF21-mimetic antibody activating the βKlotho/FGFR1c receptor complex.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

BetaKlotho is required for metabolic activity of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

FGF21 induces PGC-1alpha and regulates carbohydrate and fatty acid metabolism during the adaptive starvation response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Alteration of hepatic nuclear receptor-mediated signaling pathways in hepatitis C virus patients with and without a history of alcohol drinking

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Activation of Liver FGF21 in hepatocarcinogenesis and during hepatic stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

FGF21 reloaded: challenges of a rapidly growing field

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Fibroblast growth factor 21: from pharmacology to physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Alcoholic liver disease: pathogenesis and new therapeutic targets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

"Second hit" models of alcoholic liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Genetics of alcoholic liver disease and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Peroxisome proliferator-activated receptor alpha (PPARalpha) agonist treatment reverses PPARalpha dysfunction and abnormalities in hepatic lipid metabolism in ethanol-fed mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Endocrine regulation of the fasting response by PPARalpha-mediated induction of fibroblast growth factor 21

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

PPARalpha is a key regulator of hepatic FGF21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Free fatty acids link metabolism and regulation of the insulin-sensitizing fibroblast growth factor-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

FGF-21 as a novel metabolic regulator

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

The metabolic state of diabetic monkeys is regulated by fibroblast growth factor-21.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Fibroblast growth factor 21 corrects obesity in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Animals models of gastrointestinal and liver diseases. Animal models of alcohol-induced liver disease: pathophysiology, translational relevance, and challenges

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Nonalcoholic fatty liver disease: from steatosis to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Nonalcoholic fatty liver disease and hepatocellular carcinoma: a weighty connection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Adipocyte fatty acid binding protein levels relate to inflammation and fibrosis in nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Cytokeratin-18 fragment levels as noninvasive biomarkers for nonalcoholic steatohepatitis: a multicenter validation study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

High serum level of fibroblast growth factor 21 is an independent predictor of non-alcoholic fatty liver disease: a 3-year prospective study in China

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Obesity is a fibroblast growth factor 21 (FGF21)-resistant state

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Circulating FGF-21 levels in normal subjects and in newly diagnose patients with Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Serum FGF21 levels are increased in obesity and are independently associated with the metabolic syndrome in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Alterations in fatty acid kinetics in obese adolescents with increased intrahepatic triglyceride content

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Therapeutic role of ursolic acid on ameliorating hepatic steatosis and improving metabolic disorders in high-fat diet-induced non-alcoholic fatty liver disease rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Fibroblast growth factor 21 is induced by endoplasmic reticulum stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

The adaptive endoplasmic reticulum stress response to lipotoxicity in progressive human nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Role of endoplasmic reticulum stress in the pathogenesis of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Endoplasmic reticulum stress and liver injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Endoplasmic reticulum stress in liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Peroxisome proliferator-activated receptor-α activation and excess energy burning in hepatocarcinogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

21 January 2018

Hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Forced expression of hepatocyte-specific fibroblast growth factor 21 delays initiation of chemically induced hepatocarcinogenesis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

FGF19-induced hepatocyte proliferation is mediated through FGFR4 activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Should we consider patients with coexistent hepatitis B or C infection for orthotopic heart transplantation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Hepatitis C virus NS4B induces unfolded protein response and endoplasmic reticulum overload response-dependent NF-kappaB activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Diagnosis of nonalcoholic fatty liver disease: invasive versus noninvasive

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

The role of bright liver echo pattern on ultrasound B-mode examination in the diagnosis of liver steatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Obesity is the only independent factor associated with ultrasound-diagnosed non-alcoholic fatty liver disease: a cross-sectional case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898

Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.2014.944898